Literature DB >> 9120168

Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction.

A Cittadini1, J D Grossman, R Napoli, S E Katz, H Strömer, R J Smith, R Clark, J P Morgan, P S Douglas.   

Abstract

OBJECTIVES: We sought to investigate the cardiac effects of growth hormone (GH) administration during the early phase of pathologic remodeling in a rat model of large myocardial infarction (MI).
BACKGROUND: Recent evidence suggests that exogenous administration of GH evokes a hypertrophic response and increases left ventricular (LV) function in vivo in rats with normal or chronically failing hearts. We hypothesized that these effects would attenuate ventricular remodeling early after MI.
METHODS: Fifty-eight male rats underwent sham operation (n = 19) or had induced MI (n = 39). The day after the operation, the infarcted rats were randomized to receive 3 weeks of treatment with GH, 3 mg/kg body weight per day (n = 19) or placebo (n = 20). Echocardiography, catheterization and isolated whole heart preparations were used to define cardiac structure and function.
RESULTS: Growth hormone caused hypertrophy of the noninfarcted myocardium in a concentric pattern, as noted by higher echocardiographic relative wall thickness at 3 weeks and by morphometric histologic examination. Left ventricular dilation was reduced in the GH-treated versus placebo group (echocardiographic LV diastolic diameter to body weight ratio 2.9 +/- 0.1 vs. 3.5 +/- 0.2 cm/kg; p < 0.05). In vivo and in vitro cardiac function was improved after GH treatment. Despite elevated insulin-like growth factor-1 (IGF-1) serum levels in GH-treated rats, myocardial IGF-I messenger ribonucleic acid was not different among the three groups, suggesting that an increase in its local expression does not appear necessary to yield the observed effects.
CONCLUSIONS: These data demonstrate that early treatment of large MI with GH attenuates the early pathologic LV remodeling and improves LV function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120168     DOI: 10.1016/s0735-1097(97)00010-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

1.  Insulin-like growth factor 1 prevents diastolic and systolic dysfunction associated with cardiomyopathy and preserves adrenergic sensitivity.

Authors:  S R Roof; J Boslett; D Russell; C del Rio; J Alecusan; J L Zweier; M T Ziolo; R Hamlin; P J Mohler; J Curran
Journal:  Acta Physiol (Oxf)       Date:  2015-10-08       Impact factor: 6.311

2.  Growth hormone signalling and apoptosis in neonatal rat cardiomyocytes.

Authors:  Y Gu; Y Zou; R Aikawa; D Hayashi; S Kudoh; T Yamauchi; H Uozumi; W Zhu; T Kadowaki; Y Yazaki; I Komuro
Journal:  Mol Cell Biochem       Date:  2001-07       Impact factor: 3.396

Review 3.  Therapeutic potential of ghrelin in the treatment of heart failure.

Authors:  Noritoshi Nagaya; Kenji Kangawa
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction.

Authors:  Rosemeire M Kanashiro-Takeuchi; Konstantinos Tziomalos; Lauro M Takeuchi; Adriana V Treuer; Guillaume Lamirault; Raul Dulce; Michael Hurtado; Yun Song; Norman L Block; Ferenc Rick; Anna Klukovits; Qinghua Hu; Jozsef L Varga; Andrew V Schally; Joshua M Hare
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-21       Impact factor: 11.205

5.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08

6.  Six-months of recombinant human GH therapy in patients with ischemic cardiac failure.

Authors:  Sjoerd W van Thiel; Jan W A Smit; Albert de Roos; Jeroen J Bax; Ernst E van der Wall; Nienke R Biermasz; Eric Viergever; Hubert W Vliegen; Johannes A Romijn; Ferdinand Roelfsema; Hildo J Lamb
Journal:  Int J Cardiovasc Imaging       Date:  2004-02       Impact factor: 2.357

7.  Effects of short-term treadmill exercise training or growth hormone supplementation on diastolic function and exercise tolerance in old rats.

Authors:  Leanne Groban; Harrison Jobe; Marina Lin; Timothy Houle; Dalane A Kitzman; William Sonntag
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2008-09       Impact factor: 6.053

Review 8.  Cardiovascular effects of growth hormone.

Authors:  W J Brickman; B L Silverman
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.925

9.  Regenerative therapies using cell sheet-based tissue engineering for cardiac disease.

Authors:  Yuji Haraguchi; Tatsuya Shimizu; Masayuki Yamato; Teruo Okano
Journal:  Cardiol Res Pract       Date:  2011-10-06       Impact factor: 1.866

Review 10.  Advanced Strategies for End-Stage Heart Failure: Combining Regenerative Approaches with LVAD, a New Horizon?

Authors:  Cheyenne C S Tseng; Faiz Z Ramjankhan; Nicolaas de Jonge; Steven A J Chamuleau
Journal:  Front Surg       Date:  2015-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.